Modifications of the Covid-19 vaccine
Sign up for myFT Daily Digest to be the first to know about Covid-19 vaccine issues.
Pfizer said it was expected to register in November for the US to approve its Covid-19 vaccine for children between the ages of six months and five years as it rushes to expand its jab capacity.
The vaccine, developed in collaboration with BioNTech, was first Permitted for use for children aged 12 and over, and Pfizer had previously said it wanted to light a green light from the U.S. Food and Drug Administration for children aged 5 to 11 in early October.
On Tuesday, Pfizer gave the first indication of when he wants to pursue a jab in children as young as six months. Frank D’Amelio, chief financial officer, told a corporate meeting that the company hopes to “go to the top” for these ages in November.
“We look forward to living. . . More information for children between the ages of six months and five years can be submitted to the FDA, “says D’Amelio.
Speaking at the Morgan Stanley Global Healthcare Conference on Tuesday, D’Amelio added that the deadline considered “everything is fine”.
Vaccination of infants is seen as an important part of reducing the epidemic as child care centers and schools can become breeding grounds for the virus. And the prevalence of Covid disease and the increasing number of hospitals in the US have boosted vaccination rates for children, particularly in schools. reopen for the autumn.
Last week on August 14, the number of hospitalizations for Covid among children under four years of age and below was almost double the rate of the last week on June 26, according to reports published last week by the Centers for Disease Control and Prevention.
Recent cases of coronavirus
Follow FT’s description of the global epidemic and the rapidly changing economic crisis Pano.
However, according to the most recent data reserved in the US, the number of children aged 0-4 in the hospital was 2.2 per 100,000, compared with 15.8 per 100,000 among those with more than 65 vaccines.
Scott Gottlieb, director of Pfizer and former FDA Commissioner, confirmed the details of D’Amelio’s offer. Speaking at a Financial Times conference on Tuesday, he said the legal approval of the BioNTech / Pfizer jab for children as young as six months could come “by the end of 2021, early 2022”.
The BioNTech / Pfizer Jabu for young children is stronger than the others. In clinical trials, infants between the ages of 6 and 5 months are given 3 micrograms, compared with 10 micrograms for children aged 5 to 11 and 30 micrograms for adults.